Le Lézard
Classified in: Health
Subject: SVY

Global Gastrointestinal Symptoms Partnering 2010 to 2017


LONDON, Nov. 17, 2017 /PRNewswire/ --The Global Gastrointestinal Symptoms Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

Download the full report: https://www.reportbuyer.com/product/3605696

? Trends in partnering deals
? Top deals by value
? Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Download the full report: https://www.reportbuyer.com/product/3605696

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 11:15
Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures....

at 11:03
The heart of Vajra Coffee's natural decaffeination process lies in its adoption of the Swiss Water® Process, a natural method that removes 99% of caffeine...

at 11:00
United Imaging Healthcare (SSE:688271) has published its 2023 Environment, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. This report highlights the company's advancements in corporate responsibility,...

at 11:00
United Imaging Healthcare (SSE:688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report. The report reveals that the company achieved 11.41 billion CNY in revenue in 2023,...

at 10:54
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...

at 10:49
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...



News published on and distributed by: